Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 10, 1999, Pages 691-696

  Bierbaum, G ^a   Fuchs, K ^a   Lenz, W ^a   Szekat, C ^a   Sahl, H G ^a  

^a Inst fur Med M I der U B   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA FRAGMENT; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; GERMANY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0032751635     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050380     Document Type: Article

References (21)

1. 1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy (1997) 40:135-146
2. 2. Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report (1997) 46:765-766
3. 3. Centers for Disease Control and Prevention: Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report (1997) 46:813-815
4. 4. Robert-Koch-Institut: Erstes Auftreten von MRSA mit verminderter Glykopeptidresistenz in Deutschland nachgewiesen. Epidemiologisches Bulletin (1998) 17:123
5. 5. Arthur M, Reynolds P, Courvalin P: Glycopeptide resistance in staphylococci. Trends in Microbiology (1996) 4:401-407
6. 6. Noble WC, Virani Z, Cree RGA: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters (1992) 93:195-198
7. 7. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, Clark NC, Hiramatsu K: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. Journal of Clinical Microbiology (1998) 36:1020-1027
8. 8. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K: Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. Journal of Antimicrobial Chemotherapy (1998) 42:315-320
9. 9. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Journal of Antimicrobial Chemotherapy (1998) 42:199-209
10. 10. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 350:1670-1673
11. 11. Goering RV, Duensing TD: Rapid field inversion gel electrophoresis in combination with an rRNA gene probe in the epidemiological evaluation of staphylococci. Journal of Clinical Microbiology (1990) 28:426-429
12. 12. Kohlrausch U, Höltje JV: One-step purification procedure for UDP-N-acetylmuramyl-peptide murein precursors from Bacillus cereus. FEMS Microbiology Letters (1991) 78:253-258
13. 13. Hiramatsu K: Vancomycin resistance in staphylococci. Drug Resistance Updates (1998) 1:135-150
14. 14. McCormick MH, Stark WM, Pittenger GE, Pittenger RC, McGuire JR: Vancomycin, a new antibiotic. I. Chemical and biological properties. Antibiotics Annual (1956) 1955-1956:601-611
15. 15. Kirst HA, Thompson DG, Nicas TI: Historical yearly usage of vancomycin. Antimicrobial Agents and Chemotherapy (1998) 42:1303-1304
16. 16. Daum RS, Gupta S, Sabbagh R, Milewski WM: Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. Journal of Infectious Diseases (1992) 166:1066-1072
17. +-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy (1996) 40:166-172
18. 18. Moreira B, Boyle-Vavra S, de Jonge BLM, Daum RS: Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy (1997) 41:1788-1793
19. 19. Sieradzki K, Tomasz A: Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. Journal of Bacteriology (1997) 179:2557-2566
20. 20. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV: Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrobial Agents and Chemotherapy (1993) 37:2432-2437
21. 21. Mainardi J-L, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW: Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. Journal of Infectious Diseases (1995) 171:1646-1650